A diagnostic and therapeutic approach to primary burning mouth syndrome

Clin Dermatol. 2017 Sep-Oct;35(5):453-460. doi: 10.1016/j.clindermatol.2017.06.006. Epub 2017 Jun 24.

Abstract

Primary burning mouth syndrome (BMS) is an oral mucosal disorder that is characterized by a chronic and often debilitating intraoral burning sensation for which no localized or systemic cause can be found. BMS most commonly affects postmenopausal women. The pathophysiology of primary BMS is not well understood. Diagnosing BMS can prove to be challenging. BMS patients can also pose a therapeutic challenge to clinicians who are consulted to evaluate these patients. Most commonly used therapies include tricyclic antidepressants, α-lipoic acid, clonazepam, and cognitive-behavioral therapy. Clinical judgment, patient counseling, and monitoring of pain are important. Further research is required to assess the effectiveness of serotonin and newer serotonin-noradrenalin reuptake inhibitors.

Publication types

  • Review

MeSH terms

  • Antidepressive Agents, Tricyclic / therapeutic use
  • Antioxidants / therapeutic use
  • Burning Mouth Syndrome / diagnosis*
  • Burning Mouth Syndrome / therapy*
  • Clonazepam / therapeutic use
  • Cognitive Behavioral Therapy
  • Female
  • GABA Modulators / therapeutic use
  • Humans
  • Thioctic Acid / therapeutic use

Substances

  • Antidepressive Agents, Tricyclic
  • Antioxidants
  • GABA Modulators
  • Clonazepam
  • Thioctic Acid